The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1018
January 16, 1998
View Complete Issue         Table of Contents 2019 
Cerivastatin for Hypercholesterolemia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Cerivastatin for Hypercholesterolemia
January 16, 1998 (Issue: 1018)
Cerivastatin (Baycol - Bayer), a new HMG-CoA reductase inhibitor (or "statin"), has been approved by the FDA for treatment of hypercholesterolemia. Cerivastatin is the sodium salt of a synthetic fluorophenyl pyridinyl-substituted heptanoic...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Cerivastatin for Hypercholesterolemia
Article code: 1018a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.